a Kyle Bass has lost a battle, but not the war, in his fight with Big Pharma

... fees. Last week, the first decision came down against Bass, regarding his attempt to invalidate a patent held by Ardsley, New York-based Acorda Therapeutics (Nasdaq: ACOR) for the drug, Ampyra. But according to Lana Gladstein , a partner in the ...
http://ift.tt/1UkH3GT